pegunigalsidase alfa较市售酶替代治疗药对小纤维神经病有阳性效果
发布时间：2018-10-12 10:15
【摘要】：正Protalix生物治疗药公司宣布,在小鼠法布雷病模型上pegunigalsidase alfa,与市售酶替代治疗药及未给予治疗的小鼠比较,证实可延缓小纤维神经病发展。此次临床前研究中,该药1 mg/kg、市售药β阿加糖苷酶(Fabrazyme)和α阿加糖苷酶(Replagal)分别为1和0.2 mg/kg,给法布雷病小鼠每2周1次静脉滴注,与不给药法布雷病小鼠和野生型健康小鼠进行比较,共3个月。用α半乳糖苷酶治疗的法布雷病小鼠,与不给药法
[Abstract]:Protalix Biotherapeutic Drug Company announced that pegunigalsidase alfa, could delay the development of microfibrillary neuropathy in mice with Fabr's disease model compared with those sold on the market and without treatment. In this preclinical study, 尾 -agar glucosidase (Fabrazyme) and 伪 -agar glucosidase (Replagal) were 1 and 0. 2 mg/kg, respectively by intravenous drip once every 2 weeks in mice with Fabr's disease. The results were compared with the control mice and the wild type healthy mice for 3 months. Fabr disease mice treated with 伪 galactosidase
【分类号】：R971
本文编号：2265747
[Abstract]:Protalix Biotherapeutic Drug Company announced that pegunigalsidase alfa, could delay the development of microfibrillary neuropathy in mice with Fabr's disease model compared with those sold on the market and without treatment. In this preclinical study, 尾 -agar glucosidase (Fabrazyme) and 伪 -agar glucosidase (Replagal) were 1 and 0. 2 mg/kg, respectively by intravenous drip once every 2 weeks in mice with Fabr's disease. The results were compared with the control mice and the wild type healthy mice for 3 months. Fabr disease mice treated with 伪 galactosidase
【分类号】：R971
【相似文献】
相关期刊论文 前1条
1 刘安珍,赵保生,于子风,王家彬;氨基糖甙类抗生素不同给药法疗效比较[J];临床荟萃;1997年18期
，本文编号：2265747
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2265747.html
最近更新
教材专著
